Ascendis Pharma A/S (ASND) Stock Price, Financials & Summary

Price chart

Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14

Key dataSep 14, 2026

Open$265.00

From 52W high−4.42%

Volume400112.00

Market cap$17.43B

P/E (TTM)18.9x

P/S (TTM)14.3x

Div yield—

Key dataSep 14, 2026

Open

$265.00

From 52W high

−4.42%

Volume

400112.00

Market cap

$17.43B

ValuationView details →

P/E (Fwd)

36.6x

EV/EBITDA

187.7x

P/E (TTM)

18.9x

RSI (14)

54.9

MomentumView details →

1D Return

+0.53%

YTD Return

+23.23%

SummaryUpdated Jun 1, 2026

Ascendis Pharma A/S (NASDAQ:ASND) is a Danish biopharmaceutical company founded in 2006 and headquartered in Hellerup, Denmark. The company went public on NASDAQ in January 2015. Ascendis specializes in developing innovative therapeutics for rare endocrine diseases using its proprietary TransCon technology platform, which enables the creation of long-acting versions of existing drugs. The company has successfully commercialized two products and maintains a robust pipeline of treatments targeting unmet medical needs in endocrinology and oncology.

Ask drillr about Ascendis Pharma A/S →

ValuationView details →

P/E (Fwd)

36.6x

P/E (TTM)

18.9x

EV/EBITDA

187.7x

EV/Sales

13.9x

P/S (TTM)

14.3x

P/B (TTM)

10.5x

ProfitabilityView details →

Gross Margin

90.19%

Net Margin

71.69%

EBITDA Margin

7.41%

ROE (TTM)

52.64%

ROA (TTM)

33.08%

Asset Turnover

0.49x

GrowthView details →

Revenue YoY

+114.85%

EPS YoY

+365.93%

FCF YoY

+297.19%

Revenue CAGR 3Y

+138.21%

EPS CAGR 3Y

+44.56%

EBITDA YoY

+151.76%

MomentumView details →

1D Return

+0.53%

YTD Return

+23.23%

1Y Return

+35.02%

RSI (14)

54.9

vs 50D SMA

+2.14%

vs 200D SMA

+12.40%

Capital & dividendView details →

Debt/Equity

0.31x

Current Ratio

2.99x

Quick Ratio

2.32x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$3.29

EPS Surprise

117.88%

Beats (12Q)

7/12

Next Q EPS Est

$1.10

Avg Surprise (4Q)

−245.44%

Rev Surprise

1.18%

Financials snapshotView financials →

Revenue (TTM)

1.05B

Net Income (TTM)

755.85M

Op. CF (TTM)

351.32M

Next earningsNov 11, 2026 →

Latest newsMore news →

Ascendis Pharma A/S announced that its Board of Directors authorized a share repurchase program of up to $400 million of its ordinary shares.14h ago

Ascendis Pharma will regain all rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, and plans to initiate multiple programs in those areas including obesity.14h ago

Similar companies

Shanghai Junshi Biosciences Co., Ltd.01877.HK 神州细胞688520.SH Metis Techbio-p07666.HK 康希诺688185.SH Jazz Pharmaceuticals plcJAZZ 大参林603233.SH Find similar companies →

Latest newsMore news →

Ascendis Pharma A/S announced that its Board of Directors authorized a share repurchase program of up to $400 million of its ordinary shares.14h ago Ascendis Pharma will regain all rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, and plans to initiate multiple programs in those areas including obesity.14h ago